Cite
HARVARD Citation
Clark, C. et al. (2018). Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy. Bone marrow transplantation. pp. 1589-1592. [Online].